Osteoarthritis (OA) is a chronic condition characterized by pain during joint movement. Additionally, patients with advanced disease experience pain at rest (ie, ongoing pain) that is generally resistant to nonsteroidal antiinflammatory drugs. Injection of monosodium iodoacetate (MIA) into the intraarticular space of the rodent knee is a well-established model of OA that elicits weight-bearing asymmetry and referred tactile and thermal hypersensitivity. Whether ongoing pain is present in this model is unknown. Additionally, the possible relationship of ongoing pain to MIA dose is not known. MIA produced weight asymmetry, joint osteolysis, and cartilage erosion across a range of doses (1, 3, and 4.8 mg). However, only rats treated with the highest dose of MIA showed conditioned place preference to a context paired with intraarticular lidocaine, indicating relief from ongoing pain. Diclofenac blocked the MIA-induced weight asymmetry but failed to block MIA-induced ongoing pain. Systemic AMG9810, a transient receptor potential V1 channel (TRPV1) antagonist, effectively blocked thermal hypersensitivity, but failed to block high-dose MIA-induced weight asymmetry or ongoing pain. Additionally, systemic or intraarticular HC030031, a TRPA1 antagonist, failed to block high-dose MIA-induced weight asymmetry or ongoing pain. Our studies suggest that a high dose of intraarticular MIA induces ongoing pain originating from the site of injury that is dependent on afferent fiber activity but apparently independent of TRPV1 or TRPA1 activation. Identification of mechanisms driving ongoing pain may enable development of improved treatments for patients with severe OA pain and diminish the need for joint replacement surgery.
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Introduction
Osteoarthritis (OA) is characterized by progressive loss of articular cartilage, new bone formation, and synovial proliferation that can result in pain, loss of joint function, and diminished quality of life [1] . Pain is the key complaint for OA patients, is the driving factor for visiting a primary care physician, and is why many patients ultimately choose to undergo joint replacement surgery [21] . OA pain is often comprised of hyperalgesia, referred pain, and ongoing pain (pain at rest) [19] . OA patients report pain that can be broadly characterized into 2 categories: (1) dull aching, throbbing pain that becomes more constant over time; and (2) shorter episodes of more intense or sharp pain, that become more frequent over time [21, 22] . Early OA pain is characterized by predictable sharp or other pain, usually brought on by a trigger, whereas advanced OA is characterized by constant dull/ aching pain that is punctuated by short episodes of often unpredictable intense pain [21] . OA pain is primarily treated with lifestyle changes, followed by pharmacological interventions including acetaminophen, nonsteroidal antiinflammatory drugs (NSAIDs), topical agents, intraarticular injections (eg, steroids), and with nonpharmacological interventions, such as joint replacement, in cases where patients are not responsive to pharmacological therapy [11, 12, 36] .
Injection of monosodium iodoacetate (MIA) into the intraarticular space of the knee is an established and well-characterized preclinical model of OA [8, 23, 33, 42] . Intraarticular MIA elicits transient inflammation followed by joint destruction consistent with clinical OA [23, 33] . Previous studies using this model have demonstrated that intraarticular MIA results in decreased weight bearing on the injured limb, movement-evoked pain, and hypersensitivity to acute application of noxious (hyperalgesia) and nonnoxious (allodynia) stimulation to the hind paw, suggesting referred pain [8, 9, 42] . We recently used a high dose of intraarticular MIA in an attempt to model advanced OA. Our
